American Cancer Society calls for more balance in reporting of tamoxifen risk studyBMJ 2009; 339 doi: http://dx.doi.org/10.1136/bmj.b3538 (Published 01 September 2009) Cite this as: BMJ 2009;339:b3538
- Janice Hopkins Tanne
- 1New York
The American Cancer Society has said that tamoxifen prevents far more second breast cancers and deaths than it causes. The society was responding to media headlines triggered by a US study showing a rise in numbers of oestrogen receptor negative breast cancers in the contralateral breast in women who had been taking tamoxifen for five years or longer.
The study, conducted by the Fred Hutchinson Cancer Center in Seattle, Washington, reported that women who took tamoxifen for more than five years after treatment for primary oestrogen receptor positive breast cancer had a fourfold higher risk of oestrogen receptor negative breast cancer, which is more difficult to treat, in the opposite breast (Cancer Research 2009;69:6865-70, doi:10.1158/0008-5472.CAN-09-1355).
The observational study …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial